Barw Barw Medical Journal 2960-1959 2024 06 23 Efficacy of Sorafenib in the Management of Non-Small Cell Lung Cancer: A Systematic Review 10.58742/bmj.v2i2.92 eng Rebaz M. Ali Hiwa Cancer Hospital, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq. rebaz.ali12@gmail.com Sami S. Omar Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq. sami.omar@gmail.com Fahmi H. Kakamad College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. fahmi.hussein@univsul.edu.iq Diyar A. Omar Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Kurdistan, Iraq. diyar.omar@gmail.com Yousif M. Mahmood Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. yousuf.smarthealth@gmail.com Mohammed Q. Mustafa Department of Medical Analysis, Tishk International University, Erbil, Kurdistan, Iraq . mohammed111@gmail.com Aland S. Abdullah College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. aland.abdullah@gmail.com Marwan N. Hassan Kscien Organization for Scientific Research (Middle East Office), Hamid Street, Azadi Mall, Sulaymaniyah, Kurdistan, Iraq. marwan.nasih12@gmail.com Hiwa O. Abdullah Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. hiewaom96@gmail.com Hawbash M. Rahim Department of Medical Laboratory Science, College of Health Sciences, University of Human Development, Kurdistan Region, Sulaymaniyah, Iraq. hawbash.mhamad96@gmail.com Rawezh Q. Salih Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. rawezh.salih@gmail.com Berun A. Abdalla Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. berun.anwer95@gmail.com 2024 04 10 Introduction The current standard treatment approach for non-small cell lung cancer (NSCLC) is surgery. Recently, targeted therapy has emerged as a promising new treatment option. In this systematic review, the efficacy of sorafenib, when given alone or combined with erlotinib, in managing NSCLC is reviewed. Methods To identify English language studies published up to March 8th, 2024, the Google Scholar, CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE databases were screened, and the data were assessed. Results The systematic search revealed 208 papers; however, only 10 were eligible to be included. The sample size was 1080 patients, of which 848 were in the sorafenib group, and 232 were in the sorafenib with erlotinib combination group. In the sorafenib group, the partial response was 2.4%, stable disease was reported in 25%, and 56 cases (6.6%) had progressive disease. In the combination group, partial response, stable disease, and progressive disease were 16.8%, 48.3%, and 19.8%, respectively. In the combination group, the median overall survival was 231 days, and the progression-free survival (PFS) was 141 days. However, in the sorafenib group, the median overall survival was 180 days, and the PFS was 82 days. Fatigue was the most common adverse event, reported in 325 (30.1%) patients. Among them, 235 cases (27.7%) were in the sorafenib group, and 90 cases (38.8%) were in the combination group. Conclusion Combination therapy may result in better overall survival and PFS than sorafenib alone, with slightly similar adverse events.